Azitra, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AZTR research report →
Price Chart
About the company
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases.
- CEO
- Francisco D. Salva
- IPO
- 2023
- Employees
- 13
- HQ
- Branford, CT, US
Get TickerSpark's AI analysis on AZTR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.40M
- P/E
- -0.10
- Fwd P/E
- 0.76
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.34
- EV/EBITDA
- 0.94
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -205.45%
- ROIC
- -159.45%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-10,966,665
- Net Income
- $-10,955,370-22.2%
- EPS
- $-2.25+85.7%
- OCF Growth
- -10.2%
- FCF Growth
- -8.0%
- 52W High
- $1.09
- 52W Low
- $0.10
- 50D MA
- $0.15
- 200D MA
- $0.20
- Beta
- -1.04
- RSI (14)
- 36
- Avg Volume
- 1.73M
No earnings-call transcripts are available for AZTR yet.
- Free Float
- 94.9%
- Shares Outstanding
- 10.74M
- Float Shares
- 10.19M
of shares held by institutions
7 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Dauntless Investment Group, LLC | 11.29M | ▲ 11.29M |
| Stonepine Capital Management, LLC | 5.29M | ▲ 5.29M |
| Nantahala Capital Management, LLC | 2.21M | ▲ 2.21M |
| Jane Street Group, LLC | 248.43K | ▲ 248.43K |
| Geode Capital Management, LLC | 95.41K | ▼ 374.47K |
| Citadel Advisors LLC | 86.24K | ▲ 86.24K |
| Virtu Financial LLC | 64.94K | ▲ 64.94K |
| Ubs Group AG | 50.48K | ▲ 20.28K |
| Stonex Group Inc. | 28.65K | ▲ 6.19K |
| Tower Research Capital LLC (Trc) | 19.50K | ▲ 4.42K |
| Ci Private Wealth, LLC | 14.45K | ▲ 14.45K |
| Susquehanna International Group, Llp | 12.24K | ▲ 12.24K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Salva Francisco D. | other | 4,064,050 |
| Jun 16, 26 | Salva Francisco D. | other | 500 |
| Apr 20, 26 | Staskey Norm | other | 35,524 |
| Apr 20, 26 | Salva Francisco D. | other | 220,879 |
| Apr 20, 26 | Whitfill Travis | other | 64,300 |
| Mar 18, 26 | Salva Francisco D. | buy | 4,064,050 |
| Mar 18, 26 | Salva Francisco D. | buy | 4,064,050 |
| Mar 18, 26 | Salva Francisco D. | buy | 500 |
| Dec 19, 25 | Whitfill Travis | other | 23,724 |
| Dec 19, 25 | Salva Francisco D. | other | 59,309 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AZTR coverage
Recent articles, reports, and earnings notes.
No research on AZTR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AZTR report →Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
prnewswire.com · Oct 1
Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Significant Drop in Short Interest
defenseworld.net · Sep 29
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 8
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
prnewswire.com · Aug 21
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
prnewswire.com · Aug 12
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
prnewswire.com · Jul 15
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
prnewswire.com · Jun 17
Azitra, Inc. to Present at 2026 BIO International Convention
prnewswire.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.